Carla Van Den Berg, Pharm.D.
Co-Director of Developmental Therapeutics Lab, Livestrong Cancer Institutes
Associate Chair for Research, Department of Oncology
Courtesy Associate Professor, Department of Oncology
Ph.D., Pharmacy
University of Texas Health Science Center at San Antonio & University of Texas-Austin
Fellowship, Oncology Research
University of Texas Health Sciences Center, San Antonio, TX
Fellowship, Oncology Research
Cancer Therapy & Research Center, San Antonio, TX
About
Carla VanDenBerg’s research interests include receptor tyrosine kinases (RTKs) convey pro-tumorigenic responses in breast, colon, lung and prostate cancer. Her lab focuses on a group of proteins known as JNK (c-Jun N-terminal Kinases) which are activated by receptor tyrosine kinases in breast cancer models. Ultimately, VanDenBerg and her team hope to evaluate if JNK can be therapeutically targeted to treat breast cancer patients.
-
American Association of Cancer Research
-
American Society of Biochemistry and Molecular Biology
-
University of Colorado Cancer Center
-
Phi Lambda Sigma, University of Colorado Chapter
-
Rhone-Poulenc Rorer Research Award, 1997
American College of Clinical Pharmacy -
New Investigator Award, 1997
American Association of Colleges of Pharmacy -
Pharmacy Research Award, Postdoctoral Training Programs, 1995
The University of Texas, College of Pharmacy -
T-32 Research Training Grant, 1993, 1995
National Cancer Institute -
Cetus Oncology Research Award, 1993
American College of Clinical Pharmacy